Anamar Ab

Chiron Corporation

Action Pharma A/s

Pharmacia Ab

Pharmacia & Upjohn Ab

Kabivitrum Ab

Acure Pharma Ab

Anna Skottner

Torbjörn Lundstedt

Elisabeth Seifert

Victor Andrianov

Arne Boman

Per Andersson

Peter David Gluckman

Linda Fryklund

Vibeke Arrhenius-Nyberg

Kjell Malmlof

Ivars Kalvins

Hans Arne Hansson

Martin Kanje

The present invention relates to the use of compounds of general formula (I) as ligands to the melanocortin receptors and/or for treatment of disorders in the melanocortin system: wherein X is H or OH; R, R, R, Rand Rare the same or different and are selected from hydrogen, halogen, alkyl having 1 to 5 carbon atoms, electron donor groups such as alkoxy having 1-5 carbon atoms or hydroxy, electron acceptor groups selected from cyano, nitro, trifluoroalkyl or amide; alkylamino, benzoyloxy, nitroxy, phenyl or sulpho; and the pharmacologically active salts thereof.

Method of treating inflammation

The present invention relates to the use of compounds of general formula (I) as ligands to the melanocortin receptors and/or for treatment of disorders in the melanocortin system: wherein X is H or OH; R1, R2, R3, R4 and R5 are the same or different and are selected from hydrogen, halogen, alkyl having 1 to 5 carbon atoms, electron donor groups such as alkoxy having 1-5 carbon atoms or hydroxy, electron acceptor groups selected from cyano, nitro, trifluoroalkyl or amide; alkylamino, benzoyloxy, nitroxy, phenyl or sulpho; and the pharmacologically active salts thereof. 

Method for treating arthritis

Use of benzylideneaminoguanidines and hydroxyguanidines as melanocortin receptor ligands

The present invention relates to the use of compounds of general formula (I) as ligands to the melanocortin receptors and/or for treatment of disorders in the melanocortin system: wherein X is H or OH; R1, R2, R3, R4 and R5 are the same or different and are selected from hydrogen, halogen, alkyl having 1 to 5 carbon atoms, electron donor groups such as alkoxy having 1-5 carbon atoms or hydroxy, electron acceptor groups selected from cyano, nitro, trifluoroalkyl or amide; alkylamino, benzoyloxy, nitroxy, phenyl or sulpho; and the pharmacologically active salts thereof.

The present invention provides novel compounds of the general Formula (I) as ligands to the melanocortin receptors and/or for treatment of disorders in the melanocortin system:  

N-phenylpyrrole guanidine derivatives as melanocortin receptor ligands

The present invention provides novel compounds of the general Formula (I) as ligands to the melanocortin receptors and/or for treatment of disorders in the melanocortin system: wherein X is (CH)where n is 0, 1 or 2; 

The present invention provides novel compounds and use of compounds of general formula (I) as ligands to the melanocortin receptors and/or for treatment of disorders in the melanocortin system: Wherein X and Y are independently chosen from O, N, S and (CH), where n is 0, 1, 2, 3, 4, or 5, or a combination of these and may contain carbon-carbon multiple bonds and branched chains as well as alicyclic and heterocyclic groups; Q is H or OH; Rand Rcan be either the same or different and are chosen from hydrogen or the residue of an aromatic group as listed in Scheme 1 and the pharmacologically active salts thereof 

Compounds acting as melanocortin receptor ligands

Treatment of catabolic states using authentic IGF-1 and hypocaloric

A combination of insulin and an insulin-like growth factor I (IGF-I) as used in the manufacture of a medicament for counteracting a decrease in nitrogen balance and for counteracting a decrease in protein synthesis. The medicament can be used for the treatment of catabolism which is a protein catabolism due to glucocorticoid excess.

Use of insulin and IGF-I

Use of insulin and IGF-1

Use of human IGF-1 to treat cardiac disorders

A method for improving the regeneration of transected peripheral nerves in mammals and man, by administering a sufficient amount of insulin-like growth factor 1 (IGF-1) to a mammalian host in need of such treatment. If desired, administration of the medicament containing insulin like growth factor can be carried out locally by infusion.

Growing community of inventors

Ekerö, Sweden

Anna Skottner